Naxitamab (hu3F8)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Naxitamab (hu3F8), covering 2025-06-17 to 2025-06-17. Get the full timeline:
Most recent: Clinical Trial Update: Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma [Phase 2]